Prevalence and Clinicopathologic Characteristics of Hypercalcemia in Patients With Cholangiocarcinoma

Konstantinidou, Eirini; Maurer, Jordan; Reyes, Stephanie; Baiev, Islam; Stanton, Jennifer; Nipp, Ryan David; Goyal, Lipika

doi:10.1001/jamaoncol.2023.0068

Cited by 1 publication

(2 citation statements)

References 5 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The demographic characteristics and anatomical classification of this case are in line with what has been previously reported in the literature. Literature suggests a median survival from diagnosis of hypercalcemia to be 3-5 months [ 5 , 11 ]. However, our patient lived for approximately 10 months after the initial diagnosis of hypercalcemia.…”

Section: Discussionmentioning

confidence: 99%

“…Konstantinidou et al in their study subclassified the cohort on the basis of common molecular alterations associated with cholangiocarcinoma. Isocitrate dehydrogenase 1 (IDH1) that mutated intrahepatic cholangiocarcinoma was associated with HHM [ 11 ]. A few cases of HHM in patients with FGFR2 fusion (21%) have been reported, but no statistically significant associations between FGFR2 fusion-positive cholangiocarcinoma and HHM have been found [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Case of Fibroblast Growth Factor Receptor Fusion-Positive Intrahepatic Cholangiocarcinoma With Humoral Hypercalcemia of Malignancy

Chauhan,

Likasitwatanakul,

Ahmed

et al. 2024

Cureus

View full text Add to dashboard Cite

Humoral hypercalcemia of malignancy (HHM) comprises the majority of cases with malignancy-related hypercalcemia and is mediated by elevated parathyroid hormone-related peptide (PTHrP). HHM is rare in cholangiocarcinoma and has been reported only in a few case reports and series. We report a case of a 63-year-old male with a history of locally advanced fibroblast growth factor receptor (FGFR) fusion-positive intrahepatic cholangiocarcinoma who presented with recurrent HHM. The first episode of his hypercalcemia occurred 15 months after the initial diagnosis of cholangiocarcinoma and coincided with disease progression. The hypercalcemia was treated with zoledronic acid, and an FGFR inhibitor was started for the treatment of his malignancy. The second hypercalcemia episode occurred nine months later, with evidence of further disease progression. HHM is associated with poor clinical outcomes; a high index of suspicion should be present to identify and treat this complication in cases of cholangiocarcinoma promptly. With an increased understanding of the molecular alterations underlying cholangiocarcinoma, it will also be necessary to further evaluate its co-occurrence with HHM as the specific molecular alterations in this setting could lay the groundwork for targeted therapies and improve risk stratification for these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A Case of Fibroblast Growth Factor Receptor Fusion-Positive Intrahepatic Cholangiocarcinoma With Humoral Hypercalcemia of Malignancy

Chauhan,

Likasitwatanakul,

Ahmed

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

Prevalence and Clinicopathologic Characteristics of Hypercalcemia in Patients With Cholangiocarcinoma

Abstract: This cohort study investigates clinicopathologic and prognostic associations of hypercalcemia in patients with intrahepatic or extrahepatic cholangiocarcinoma.

Cited by 1 publication

References 5 publications

A Case of Fibroblast Growth Factor Receptor Fusion-Positive Intrahepatic Cholangiocarcinoma With Humoral Hypercalcemia of Malignancy

A Case of Fibroblast Growth Factor Receptor Fusion-Positive Intrahepatic Cholangiocarcinoma With Humoral Hypercalcemia of Malignancy

Contact Info

Product

Resources

About